272 related articles for article (PubMed ID: 32048061)
1. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
Kirtane K; Roth MY
Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
[TBL] [Abstract][Full Text] [Related]
2. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
3. Molecular-Driven Therapy in Advanced Thyroid Cancer.
Miller KC; Chintakuntlawar AV
Curr Treat Options Oncol; 2021 Feb; 22(3):24. PubMed ID: 33569661
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
Fullmer T; Cabanillas ME; Zafereo M
Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Gland Malignancies.
Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
[TBL] [Abstract][Full Text] [Related]
8. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma.
Brose MS; Smit J; Capdevila J; Elisei R; Nutting C; Pitoia F; Robinson B; Schlumberger M; Shong YK; Takami H
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1137-47. PubMed ID: 23098114
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
Mischler K; Kneifel S; Cathomas R
Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
[TBL] [Abstract][Full Text] [Related]
11. [Advanced radioiodine-refractory differentiated thyroid cancer].
Spitzweg C; Auernhammer CJ; Geisler J; Böck S; Heinemann V; Bartenstein P; Göke B
Dtsch Med Wochenschr; 2015 Feb; 140(3):168-71. PubMed ID: 25658401
[No Abstract] [Full Text] [Related]
12. Clinical guidance for radioiodine refractory differentiated thyroid cancer.
Gild ML; Topliss DJ; Learoyd D; Parnis F; Tie J; Hughes B; Walsh JP; McLeod DSA; Clifton-Bligh RJ; Robinson BG
Clin Endocrinol (Oxf); 2018 Apr; 88(4):529-537. PubMed ID: 29095527
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory thyroid cancer.
Berdelou A; Lamartina L; Klain M; Leboulleux S; Schlumberger M
Endocr Relat Cancer; 2018 Apr; 25(4):R209-R223. PubMed ID: 29371330
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
15. The Treatment of Well-Differentiated Thyroid Carcinoma.
Paschke R; Lincke T; Müller SP; Kreissl MC; Dralle H; Fassnacht M
Dtsch Arztebl Int; 2015 Jun; 112(26):452-8. PubMed ID: 26205749
[TBL] [Abstract][Full Text] [Related]
16. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
17. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).
Capdevila J; Galofré JC; Grande E; Zafón Llopis C; Ramón Y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Riesco Eizaguirre G
Clin Transl Oncol; 2017 Mar; 19(3):279-287. PubMed ID: 27704399
[TBL] [Abstract][Full Text] [Related]
18. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
20. Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer.
Riesco-Eizaguirre G; Galofré JC; Grande E; Zafón Llopis C; Ramón y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Capdevila J
Endocrinol Nutr; 2016 Apr; 63(4):e17-24. PubMed ID: 26601805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
